FindMyRecallSubscribe
Class I: serious health riskTerminated

Gilead Sciences Veklury Recall

Veklury (remdesivir) for injection, 100 mg/vial, Single-Dose Vial, Rx only, Manufacture…

Gilead Sciences, Inc. · Foster City, CA

Risk level
Class I
Reported by FDA
Jan 5, 2022
Recall ID
D-0299-2022
Check your lot numberHow we source this data

Summary

Gilead Sciences recalled Veklury starting Dec 3, 2021. The FDA classified it as Class I (serious health risk) and published enforcement report D-0299-2022 on Jan 5, 2022. Reason: Presence of Particulate Matter: investigation into a customer complaint confirmed the presence of glass particulates. Status: Terminated.

Why it was recalled

Presence of Particulate Matter: investigation into a customer complaint confirmed the presence of glass particulates.

Product description

Veklury (remdesivir) for injection, 100 mg/vial, Single-Dose Vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, NDC 61958-2901-2

Lot numbers, UPCs & expiration codes

Lots: 2141001-1A, 2141002-1A, Exp. 01/2024

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0299-2022
Classification
Class I
Status
Terminated
Recall initiated
Dec 3, 2021
FDA report date
Jan 5, 2022
Quantity
53,473 vials
Recall type
Voluntary: Firm initiated
Recalling firm
Gilead Sciences, Inc.

Original FDA data

Every field from FDA enforcement report D-0299-2022, exactly as published.

Show all FDA fields
City
Foster City
State
CA
Status
Terminated
Country
United States
Event ID
89153
Address
333 Lakeside Dr
Code information
Lots: 2141001-1A, 2141002-1A, Exp. 01/2024
Postal code
94404-1147
Report date
Jan 5, 2022
Product type
Drugs
Recall number
D-0299-2022
Classification
Class I
Recalling firm
Gilead Sciences, Inc.
Product quantity
53,473 vials
Termination date
Jul 25, 2022
Reason for recall
Presence of Particulate Matter: investigation into a customer complaint confirmed the presence of glass particulates.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Veklury (remdesivir) for injection, 100 mg/vial, Single-Dose Vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, NDC 61958-2901-2
Distribution pattern
Nationwide in the USA
Recall initiation date
Dec 3, 2021
Initial firm notification
Press Release
Center classification date
Dec 28, 2021

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0299-2022, published Jan 5, 2022. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls